Authors: Lucksamon Thamlikitkul Vichien Srimuninnimit Charuwan Akewanlop Suthinee Ithimakin Sirisopa Techawathanawanna Krittiya Korphaisarn Jomjit Chantharasamee Pongwut Danchaivijitr Nopadol Soparattanapaisarn
Publish Date: 2016/10/06
Volume: 25, Issue: 2, Pages: 459-464
Abstract
We enrolled breast cancer patients receiving AC who experienced moderate to severe nausea or vomiting during the first chemotherapy cycle Subjects were randomized to receive a 500mg ginger capsule or placebo twice a day for 5 days starting on the first day of the second AC cycle and were switched to the other treatment in the third cycle All participants also received ondansetron and dexamethasone for CINV prophylaxis Nausea severity was recorded once a day during the first 5 days of each cycle The primary outcome was reduction in nausea scoreThirtyfour subjects 68 cycles of AC were enrolled Mean range maximum nausea score in the first AC cycle was 58 40–90 Thirtythree subjects 97 received the same AC doses in the second as in the third cycle Mean ±standard error maximum nausea scores in patients receiving ginger and placebo were 3536 ±443 and 3217 ±371 respectively The difference in mean maximum nausea scores was 3 95 confidence interval −3 to 9 P = 03 There were no significant differences between ginger and placebo in terms of vomiting incidence and severity rescue medication use chemotherapy compliance and adverse eventsThe authors thank the Government Pharmaceutical Organization for providing ginger capsules and placebo Siriraj Cancer Center for providing funding support the personnel of the Division of Medical Oncology Department of Medicine Faculty of Medicine Siriraj Hospital for coordinating the study and Mr Suthipol Udompanthurak for performing statistical analyses of the data
Keywords: